[1] Trembling PM, Lampertico P, Parkes J, et al. Performance of enhanced liver fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat, 2014, 21(6):430-438.
[2] Lee HW, Yoo EJ, Kim BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol, 2014, 109(8):1241-1249.
[3] Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA, et al. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One, 2017, 12(9):e0184404.
[4] Preisser L, Miot C, Le Guillou-Guillemette H, et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology, 2014, 60: 1879-1890.
[5] Tacke F. Functional role of intrahepatic monocytesubsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair, 2012, 5: S27.
[6] Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 2012, 119: 1810-1820.
[7] Shoji H, Yoshio S, Mano Y, et al. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep, 2016, 6: 28814.
[8] European Association for the Studyof the Liver; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67: 370-398.
[9] Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem, 2004, 50: 1299-1300.
[10] Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol, 2014, 20: 16820-16830.
[11] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology, 2012, 142: 1293-1302.
[12] Degos F, Perez P, Roche B, et al. FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol, 2010, 53: 1013-1021.
[13] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015 年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[14] Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One, 2012, 7: e44930.
[15] Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One, 2017, 12(11):e0186660.
[16] Ding D, Li H, Liu P, et al. FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B. Int J Clin Exp Med, 2015, 8(11):20876-20882.
[17] Jia J, Hou J, Ding H, et al. Transient elastography compared to serum markers to predict liver fibrosis ina cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2015, 30(4):756-762.
[18] Goyal R, Mallick SR, Mahanta M, et a1. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B. J Gastroenterol Hepatol, 2013, 28(11): 1738-1745.
[19] Liu XD, Wu JL, Liang J, et al. Globuljn-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol, 2012, 18(22):2784-2792. |